Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylacetic Acid SCHEMBL38022 | 0.80 | SRC (0.62) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL465969 | 0.80 | TDP1 (0.61) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL8513250 | 0.80 | SRC (0.62) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Bicarbonate SCHEMBL19031939 | 0.79 | L3MBTL1 (0.54) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Bicarbonate SCHEMBL28144656 | 0.79 | L3MBTL1 (0.54) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL28441752 | 0.79 | TDP1 (0.54) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL8411440 | 0.78 | SRC (0.59) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL6852183 | 0.78 | SRC (0.59) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL9485695 | 0.78 | SRC (0.59) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL9750917 | 0.78 | SRC (0.59) | TDP1L3MBTL1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2012-12-20 | — | — | US | claimed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | claimed |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2006-01-05 | — | — | US | claimed |
| EP-1471919-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | claimed |
| EP-1021403-B1 | 2,3-DIOXABICYCLO 3.3.1]NONANE DERIVATIVES AND ANTIMALARIAL PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RES & DEV (IL) | 2005-04-20 | — | — | EP | claimed |
| EP-1471919-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066063-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| US-6166065-A | 2,3-dioxabicyclo[3.3.1]nonane derivatives and antimalarial pharmaceutical compositions comprising them | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2000-12-26 | — | — | US | claimed |
| EP-1021403-A2 | 2,3-DIOXABICYCLO 3.3.1]NONANE DERIVATIVES AND ANTIMALARIAL PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 2000-07-26 | — | — | EP | claimed |
| WO-1999012900-A2 | 2,3-DIOXABICYCLO[3.3.1]NONANE DERIVATIVES AND ANTIMALARIAL PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1999-03-18 | — | — | WO | claimed |
| US-5190946-A | Piperazine compounds restore sensitivity to drug resistant cancer cells | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | claimed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | claimed |
| US-20240091228-A1 | Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary Dysfunction | TOSK, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-117597139-A | Uridine phosphorylase inhibitors for preventing or treating drug-induced pulmonary dysfunction | 托斯克公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4301398-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO PREVENT OR TREAT DRUG-INDUCED PULMONARY DYSFUNCTION | Tosk, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230255971-A1 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions | TOSK, INC. | 2023-08-17 | — | — | US | disclosed |
| US-4518789-A | Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use | YU RUEY J | 1985-05-21 | — | — | US | disclosed |
| US-4101464-A | Process for preparing foamed solids using two or more azo compounds | PENNWALT CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4029615-A | AZO COMPOUNDS | PENNWALT CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-3993609-A | ACID SENSITIVE AZO PROMOTERS | PENNWALT CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255971-A1 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions | UMPS, UPP1, PNP | TDP1 383/4885L3MBTL1 2917/4885HDAC3 1939/4885 |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | CYP17A1, HSD17B7, NR5A1 | TDP1 2852/4885L3MBTL1 4769/4885HDAC3 2488/4885 |
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | CYP17A1, HSD17B7, NR5A1 | TDP1 2852/4885L3MBTL1 4769/4885HDAC3 2488/4885 |
| US-20240091228-A1 | Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary Dysfunction | UMPS, UPP1, PNP | TDP1 451/4885L3MBTL1 876/4885HDAC3 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.